Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roche
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
Major changes to Phase III Lung 100 study of PD-L1 inhibitor avelumab mean a big delay for development in first-line lung cancer, but, separately, Pfizer advances in allogeneic CAR-T therapy with partners Servier and Cellectis.
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.
Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.